Cargando…

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer

BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Goorts, Briete, Dreuning, Kelly M. A., Houwers, Janneke B., Kooreman, Loes F. S., Boerma, Evert-Jan G., Mann, Ritse M., Lobbes, Marc B. I., Smidt, Marjolein L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907188/
https://www.ncbi.nlm.nih.gov/pubmed/29669584
http://dx.doi.org/10.1186/s13058-018-0950-x
_version_ 1783315480691343360
author Goorts, Briete
Dreuning, Kelly M. A.
Houwers, Janneke B.
Kooreman, Loes F. S.
Boerma, Evert-Jan G.
Mann, Ritse M.
Lobbes, Marc B. I.
Smidt, Marjolein L.
author_facet Goorts, Briete
Dreuning, Kelly M. A.
Houwers, Janneke B.
Kooreman, Loes F. S.
Boerma, Evert-Jan G.
Mann, Ritse M.
Lobbes, Marc B. I.
Smidt, Marjolein L.
author_sort Goorts, Briete
collection PubMed
description BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson’s correlation coefficient, and interobserver agreement was tested with Cohen’s Kappa. RESULTS: Patients (n = 76; mean age 53, range 29–72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = − 0.17; p = 0.145 and reader 2 r = − 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR. CONCLUSION: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13058-018-0950-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5907188
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59071882018-04-30 MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer Goorts, Briete Dreuning, Kelly M. A. Houwers, Janneke B. Kooreman, Loes F. S. Boerma, Evert-Jan G. Mann, Ritse M. Lobbes, Marc B. I. Smidt, Marjolein L. Breast Cancer Res Research Article BACKGROUND: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability. METHODS: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson’s correlation coefficient, and interobserver agreement was tested with Cohen’s Kappa. RESULTS: Patients (n = 76; mean age 53, range 29–72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = − 0.17; p = 0.145 and reader 2 r = − 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR. CONCLUSION: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13058-018-0950-x) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-18 2018 /pmc/articles/PMC5907188/ /pubmed/29669584 http://dx.doi.org/10.1186/s13058-018-0950-x Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Goorts, Briete
Dreuning, Kelly M. A.
Houwers, Janneke B.
Kooreman, Loes F. S.
Boerma, Evert-Jan G.
Mann, Ritse M.
Lobbes, Marc B. I.
Smidt, Marjolein L.
MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
title MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
title_full MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
title_fullStr MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
title_full_unstemmed MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
title_short MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
title_sort mri-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907188/
https://www.ncbi.nlm.nih.gov/pubmed/29669584
http://dx.doi.org/10.1186/s13058-018-0950-x
work_keys_str_mv AT goortsbriete mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT dreuningkellyma mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT houwersjannekeb mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT kooremanloesfs mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT boermaevertjang mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT mannritsem mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT lobbesmarcbi mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer
AT smidtmarjoleinl mribasedresponsepatternsduringneoadjuvantchemotherapycanpredictpathologicalcompleteresponseinpatientswithbreastcancer